Claims

1. A non-vesicular preparation comprising at least one cationic amphiphile in a concentration of about 10 mM to about 600 mM, optionally at least one further amphiphile of up to about 60 mol % based on the total amphiphile concentration and optionally at least one stabilizing agent in a concentration of about 10 mM to about 600 mM in an aqueous phase, wherein said preparation is characterized by being transparent, isotropic and substantially homogeneous.

2. The preparation of claim 1, comprising at least one cationic amphiphile in a concentration of about 25 mM to about 500 mM, preferably in a concentration of about about 100 mM to about 400 mM and most preferably in a concentration of about 200 mM to about 300 mM.

3. The preparation of claim 1 or 2, comprising a stabilizing agent in a concentration of about 100 mM to about 500 mM, preferably in a concentration of about about 200 mM to about 400 mM.

4. The preparation of any one of the claims 1 to 3, wherein said cationic amphiphile is selected from lipids, lysolipids, pegylated lipids having a positive net charge.

5. The preparation of claim 4, wherein said cationic amphiphile is selected from cationic lipids with at least one tertiary amino or quaternary ammonium group such as N-[1-(2,3-diacyloxy)propyl]-N,N-dimethylamine or N-[1-(2,3-diacyloxy)propyl]-N,N,N-trimethyl ammonium.

6. The preparation of any one of the claims 1 to 5, wherein said further amphiphile has a negative or a neutral net charge.

7. The preparation of any one of the claims 1 to 6, wherein said further amphiphile is selected from sterols or lipids such as cholesterol, phospholipids, lysolipids, lysophospholipids, sphingolipids or pegylated lipids with a negative or neutral net change.

8. The preparation of claim 7, wherein the neutral amphiphile is diacylphosphatidylcholine.

9. The preparation of any one of the claims 1 to 8, wherein said stabilizing agent is selected from a sugar or an alcohol or a combination thereof such as trehalose, maltose, sucrose, glucose, lactose, dextran, mannitol or sorbitol.

10. The preparation of claim 9, wherein said stabilizing agent is trehalose or glucose.

11. The preparation of any one of the claims 1 to 10, further comprising an active compound, wherein said active compound may be hydrophilic, hydrophobic or amphipathic.

12. The preparation of claim 11, wherein said compound is a therapeutic agent, preferably camptothecin or a derivative thereof, a taxane or an other microtubuli interacting agent such as an epothilone, discodermolide, laulimalide, isolaulimalide, eleutherobin, colchicine and/or a derivative thereof, a vinca alkaloid such as vinorelbine, a platinum complex such as oxaliplatin, an anthracycline such as doxorubicin or a statin (e.g., lovastatin) and more preferably camptothecin or a derivative thereof in its carboxylate form.

13. The preparation of claim 12, wherein said therapeutic agent is in the range of about 0.1 mol % to about 20 mol %, preferably in the range of about 1 mol % to about 15 mol % and more preferably in the range of about 3 mol % to about 10 mol % based on the total amphiphile concentration.

14. The preparation of claim 11, wherein said compound is a diagnostic agent, preferably an imaging agent.

15. The preparation of claim 14, wherein said diagnostic agent is in the range of about 0.1 mol % to about 50 mol %, preferably in the range of about 10 mol % to about 50 mol % and more preferably in the range of about 30 mol % to about 50 mol % based on the total amphiphile concentration.

16. The use of a preparation of any one of the claims 1 to 15 for producing a liposome suspension.

17. A cationic liposome suspension obtainable from the preparation of any one of the claims 1 to 15.

18. Pharmaceutical composition comprising the preparation of any one of the claims 1 to 15 or a suspension of claim 17, optionally together with a pharmaceutically acceptable carrier, diluent and/or adjuvant

19. The use of a preparation of any one of the claims 1 to 15, a suspension of claim 17 or a pharmaceutical composition of claim 18 for the preparation of a medicament or a diagnostic formulation.

20. The use of claim 19 for the preparation of a medicament useful for an angiogenesis associated condition such as cancer, chronic or acute inflammatory diseases, rheumatoid arthritis, dermatitis, psoriasis or wound healing.

21. A method of producing the non-vesicular preparation of any one of the claims 1 to 15, comprising the steps of

(a) providing said cationic amphiphile, optionally said further amphiphile, optionally said stabilizing agent, optionally said active compound and an aqueous phase and

(b) subjecting the components of step a) to conditions so that an isotropic, transparent and substantially homogeneous preparation is formed.

22. The method of claim 21, wherein step b) comprises a single phase evaporation or high pressure homogenisation method.